A vaccination campaign designed to increase the uptake of HPV vaccine was instituted in chosen counties of a certain state in order to educate parents not only about the disease itself, but also about why children should be vaccinated against this viral sexually transmitted disease. At the end of the campaign, children living in counties in which it was conducted were 3 times more likely to receive the HPV vaccine compared with children living in counties where no campaign was instituted. As well, after evaluating only the counties that were part of the vaccination campaign, the researchers found that families with higher incomes were 2 times more likely to vaccinate their children against HPV compared with families with lower incomes. What conclusion can be drawn from these results?

Family income appears to be an effect modifier.

The vaccination campaign appears to have been ineffective.

The vaccination campaign is the study outcome.

The vaccine uptake is the study exposure.

Family income appears to be a confounder.

An 18-year-old woman presents for a routine check-up. She is a college student with no complaints. She has a 2 pack-year history of smoking and consumes alcohol occasionally. Her sexual debut was at 15 years of age and has had 2 sexual partners. She takes oral contraceptives and uses barrier contraception. Her family history is significant for cervical cancer in her aunt. Which of the following statements regarding cervical cancer screening in this patient is correct?

The patient should undergo screening every 3 years after she turns 21 years of age.

The patient requires annual Pap testing due to her family history of cervical cancer.

HPV testing is more preferable than Pap testing in sexually active women under 21 years of age.

It is reasonable to start Pap-test screening at the current visit and repeat it every 3 years.

The patient does not require Pap testing as long as she uses barrier contraception.

A 16-year-old girl comes to her primary care physician for an annual check-up. She has no specific complaints. Her medical history is significant for asthma. She uses an albuterol inhaler as needed. She has no notable surgical history. Her mom had breast cancer and her grandfather died of colon cancer. She received all her childhood scheduled vaccinations up to age 8. She reports that she is doing well in school but hates math. She is sexually active with her boyfriend. They use condoms consistently, and they both tested negative recently for gonorrhea, chlamydia, syphilis and human immunodeficiency virus. She asks about birth control. In addition to educating the patient on her options for contraception, which of the following is the best next step in management?

No HPV-related screening and administer HPV vaccine

Cytology and human papilloma virus (HPV) testing now and then every 3 years

No HPV-related screening as the patient is low risk

Cytology and HPV testing now and then every 5 years

Cytology now and then every 3 years

Two viruses, X and Y, infect the same cell and begin to reproduce within the cell. As a result of the co-infection, some viruses are produced where the genome of Y is surrounded by the nucleocapsid of X and vice versa with the genome of X and nucleocapsid of Y. When the virus containing genome X surrounded by the nucleocapsid of Y infects another cell, what is the most likely outcome?

Virions containing genome X and nucleocapsid X will be produced

Virions containing genome Y and nucleocapsid Y will be produced

Virions containing genome X and nucleocapsid Y will be produced

Virions containing genome Y and nucleocapsid X will be produced

A 32-year-old pregnant woman at 32 weeks gestation presents with a 2-day history of low-grade fever, headache, and myalgias. She works at a daycare where several children recently had 'slapped cheek' rash. Laboratory studies show hemoglobin 8.5 g/dL (baseline 12 g/dL), reticulocyte count 0.1%, and positive parvovirus B19 IgM. Fetal ultrasound shows hydrops fetalis with ascites, pleural effusions, and severe anemia on cordocentesis. Evaluate the pathophysiologic mechanism and management approach that best addresses both maternal and fetal complications.

Vertical transmission causing fetal aplastic crisis; intrauterine transfusion with close monitoring

Fetal cardiac failure from myocarditis; deliver immediately for neonatal intensive care

Placental insufficiency from maternal viremia; administer antivirals and corticosteroids

Maternal immune thrombocytopenia causing fetal bleeding; administer IVIG to mother

Maternal-fetal ABO incompatibility exacerbated by viral infection; plasmapheresis

A public health official must design a vaccination strategy for a refugee camp with 10,000 children under 5 years old. Resources allow for only one vaccine initially. Current diseases in the camp include measles (15 cases/week), diphtheria (5 cases/week), pertussis (20 cases/week), and rotavirus diarrhea (100 cases/week). Three children have died from measles, two from pertussis, and ten from dehydration due to diarrhea. Evaluate which vaccine should be prioritized and justify the decision.

MMR vaccine because measles has the highest case fatality rate and transmission potential

DTaP vaccine because pertussis has the highest incidence

Oral rehydration therapy instead of vaccination to address immediate mortality

Rotavirus vaccine because diarrhea has caused the most deaths

Pneumococcal vaccine because it prevents the leading cause of childhood mortality globally

A hospital infection control committee reviews a cluster of 5 cases of invasive pneumococcal disease over 6 months, all caused by serotype 19A, in vaccinated children aged 3-5 years who received all recommended doses of PCV13. All isolates show resistance to penicillin and macrolides. The committee must evaluate the outbreak and recommend interventions. Which factor most likely explains this outbreak despite appropriate vaccination?

Serotype 19A strain with capsular switching evading vaccine-induced immunity

Serotype replacement with non-vaccine serotypes after PCV7 was replaced by PCV13

Evolution of antibiotic resistance in serotype 19A reducing vaccine effectiveness

Inadequate immune response in children with undiagnosed primary immunodeficiency

Vaccine storage failure leading to loss of immunogenicity

A 65-year-old man with diabetes mellitus and chronic kidney disease presents with sudden onset right-sided facial weakness, inability to close his right eye, and loss of taste on the anterior two-thirds of his tongue. He has vesicular lesions in his right external auditory canal. He received varicella vaccine 20 years ago and had shingles on his trunk 5 years ago. Analyze the relationship between his current presentation and his varicella vaccination history.

His previous shingles and current presentation both resulted from reactivation of wild-type VZV acquired before vaccination

The varicella vaccine virus has reactivated to cause this condition

This is a bacterial infection unrelated to varicella-zoster virus

The current infection represents primary varicella despite previous vaccination

Simultaneous reactivation of vaccine and wild-type VZV strains

HPV vaccination for USMLE Step 2 CK: High-Yield Microbiology Lessons

HPV Overview - The Cancer Culprit

Virus: Double-stranded, non-enveloped DNA virus; over 150 types.
Transmission: Primarily sexual contact (including skin-to-skin).
Oncogenic (High-Risk) Strains: 16, 18 cause ~70% of cervical cancers & most other HPV-related cancers (anal, oropharyngeal).
Non-Oncogenic (Low-Risk) Strains: 6, 11 cause ~90% of anogenital warts (condylomata acuminata).
Pathogenesis: Integration into host genome. Viral proteins inactivate tumor suppressors:
- E6 → degrades p53
- E7 → inhibits Rb (Retinoblastoma protein)

⭐ High-Yield: Koilocytes on Pap smear are pathognomonic; these are squamous epithelial cells with a wrinkled, "raisinoid" nucleus and a perinuclear halo.

Koilocytes with perinuclear halos in HPV infection

HPV Vaccine - Gardasil's Guard

Type: Recombinant vaccine with L1 major capsid protein, forming non-infectious virus-like particles (VLPs).
Coverage (Gardasil-9): Protects against 9 HPV types.
- Low-risk (Genital Warts): 6, 11
- High-risk (Cancers - cervical, anal, oropharyngeal): 16, 18, 31, 33, 45, 52, 58
Administration Schedule:
- Ages 9-14: 2 doses at 0 and 6-12 months.
- Ages 15-26 or immunocompromised: 3 doses at 0, 1-2, and 6 months.

⭐ The vaccine is prophylactic, not therapeutic. It prevents initial infection but does not clear existing DNA or treat HPV-related disease.

HPV VLP vaccine mechanism: Immune responses

📌 HPV types 16 and 18 are implicated in ~70% of cervical cancers.

Dosing & Schedule - The Jab Plan

Routine Vaccination: Age 11-12 years (can start at age 9).
Catch-up Vaccination: Recommended for all through age 26.
Shared Clinical Decision-Making: For adults age 27-45 not adequately vaccinated.

⭐ For adults aged 27-45, vaccination is not routinely recommended but based on shared clinical decision-making, as new HPV infections are less common and the vaccine has lower efficacy in this group.

Efficacy & Safety - Worth a Shot?

Efficacy: Near 100% effective at preventing cervical precancer and cancer caused by vaccine-targeted HPV types (e.g., HPV 16, 18).
- Also prevents genital warts (HPV 6, 11).
- Reduces rates of anogenital and oropharyngeal cancers.
Safety Profile: Very safe.
- Common side effects: mild injection site reactions (pain, redness), headache.
- 📌 Post-vaccine syncope is common in adolescents; observe for 15 minutes.

⭐ Large-scale studies show a >85% reduction in cervical cancer prevalence among women vaccinated before age 17.

Projected cervical cancer cases averted by HPV vaccination

High‑Yield Points - ⚡ Biggest Takeaways

The Gardasil 9 vaccine targets HPV types 6, 11, 16, 18, and five other high-risk strains.

It prevents cervical, anogenital, and oropharyngeal cancers (linked to HPV 16, 18) and genital warts (from HPV 6, 11).

It is a recombinant, virus-like particle (VLP) vaccine and is not infectious.

Recommended for all adolescents at age 11-12, with catch-up vaccination up to age 26.

The vaccine is prophylactic and does not treat existing HPV infections or associated diseases.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play

HPV vaccination